期刊文献+

索拉非尼靶向治疗晚期肿瘤毒副反应的观察及护理 被引量:4

索拉非尼靶向治疗晚期肿瘤毒副反应的观察及护理
下载PDF
导出
摘要 目的总结索拉非尼靶向治疗晚期肿瘤患者毒副反应的观察和护理体会。方法对58例接受口服索拉非尼靶向治疗晚期肿瘤患者的毒副反应进行观察分析。结果 58病例中24例出现面部皮疹/皮肤剥脱,20例出现血压升高,17例出现手足综合征,6例出现胃肠道反应(腹泻),无患者死于毒副反应。结论索拉非尼能够有效地延长晚期肿瘤患者的生存时间,药物毒副反应轻微,无严重并发症。
出处 《护士进修杂志》 2012年第1期72-74,共3页 Journal of Nurses Training
关键词 索拉非尼 靶向治疗 毒副反应 观察 护理 Sorafenib Target treatment Toxicity Observation Nursing
  • 相关文献

参考文献2

二级参考文献25

  • 1[1]Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res.2004 Oct 1; 64 (19):7099-109.
  • 2[2]Strumberg D,Richly H,Hilger RA,et al.Phase Ⅰ clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43 -9006in patients with advanced refractory solid tumors.J Clin Oncol,2005,23 (5):965
  • 3[3]Ratain MJ,Eisen T,Stadler WM,et al.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuatoin trial (RDT) of Sorafenib (Bay 43-9006) in patients with advanced renal cell carcinoma (RCC).J Clin Oncol,2005,23 (16S):Abstract 4544
  • 4[4]Flaherty KT,Brose M,Schuchter L,et.Phase Ⅰ/Ⅱ trial of BAY 43-9006,carboplatin (C) and paclitaxel (P)demonstrates preliminary antitumor activity in the expansion chort of patients with metastatic melanoma.Proc Am Society Clin Oncol,2004,23:Abstract 7507
  • 5[5]Richly H,Henning BF,Kupsch P,et al.Results of a Phase Ⅰ trial of sorafenib (BAY 43 -9006) in combination with doxorubicin in patients with refractory solid tumors.Ann Oncol,2006,17 (5):866
  • 6[6]Siu LL,Awada A,Takimoto CH,et al.Phase Ⅰ trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.Clin Cancer Res,2006,12 (1):144
  • 7[7]Kupsch P,Henning BF,Passarge K,et al.Results of a phaseⅠ trial of sorafenib (BAY 43 -9006) in combination with oxaliplatin in patients with refractory solid tumors,including colorectal cancer.Clin Colorectal Cancer,2005,5 (3):188
  • 8[8]Clark JW,Eder JP,Ryan D,et al.Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor,BAY 43 -9006,in patients with advanced,refractory solid tumors.Clin Cancer Res,2005,1; 11 (15):5472
  • 9[9]Strumberg D,Awada A,Hirte H,et al.Pooled safety analysis of BAY 43 -9006 (sorafenib) monotherapy in patients with advanced solid tumors:Is rash associated with treatment outcome? Eur J Cancer,2006,42 (4):548
  • 10[10]Eisen T,Bukowski RM,Staehler M,et al.Randomized phase Ⅲ trial of Sorafenib in advanced renal cell carcinoma(RCC):Impact of crossover on survival.Proc ASCO,2006,43:Abstr 4524

共引文献66

同被引文献44

  • 1郑媛媛.肿瘤的单抗靶向疗法在国内的研究和应用进展[J].中国肿瘤生物治疗杂志,2006,13(1):70-72. 被引量:2
  • 2周爱萍,孙燕.多靶点抗肿瘤新药索拉非尼的研究进展[J].癌症进展,2006,4(6):529-533. 被引量:57
  • 3管考鹏,马建辉,孙燕.索拉非尼的毒副作用及处理[J].癌症进展,2007,5(4):370-373. 被引量:39
  • 4Azad N S, Aragon- Ching J B, Dahut W L, et al. Hand foot skinreactionincreases withcumulative sorafenib dose and withcombination anti - vascaular endothelial growth factor therapy[J]. Clin Cancer Res, 2009, 15." 1411.
  • 5Matta A,Ralhan R.Overview of current and future biologically based targeted therapies inhead and neck squamous cell carcinoma[J].Head Neck Oncol,2009,1:6.
  • 6Simader C,Ritter M,Bolz M,et al.Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration[J].Ophthalmology,2014,121(6):1237-1245.
  • 7Mittendorf EA,Alatrash G,Xiao H,et al.Breast cancer vaccines:ongoing National Cancer Institute-registered clinical trials[J].Expert Rev Vaccines,2011,10(6):755-774.
  • 8Lynch TJ Jr,Kim ES,Eaby B,et al.Epidermal growth factor receptor inhibitor-associated cutaneous toxicities:anevolving paradigm in clinical management[J].Oncologist,2007,12(5):610-621.
  • 9Hirsh V.Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lunge cancer[J].Current Oncology,2011,18(3):126-138.
  • 10Lacouture M,Melosky B.Cutaneous reactions to anticancer agents targeting the epidermal growth material protected by copright factor receptor:A dermatology-oncology perspective[J].Skin Therapy Letter,2007,12:1-5.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部